Utility of N-terminal (NT)-Brain Natriuretic Peptide (proBNP) in the Diagnosis and Prognosis of Pregnancy Associated Cardiovascular Conditions: A Systematic Review.
bnp
cardiology
eclampsia
heart failure
high risk
nt-probnp
obstetrics
peripartum cardiomyopathy
pregnancy
probnp
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
16
08
2022
accepted:
19
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
Cardiovascular disease includes many diseases such as heart failure, cardiomyopathy, valvular disease, pericardial disease, peripheral vascular disease, rheumatic heart disease, and vascular disease to name a few. Cardiovascular disease in pregnancy is on the rise especially with women being pregnant at an older age. Brain natriuretic peptide (BNP) could be a factor in determining the severity. BNP is elevated in heart failure. This study will attempt to determine the relationship between BNP and pregnancy outcomes in women with heart failure. A keyword combination search was performed using varying databases. Inclusion and exclusion criteria were implemented and relevant articles were obtained to formulate ideas to support the topic. BNP, the amino acid peptide, is secreted by both atrial and ventricular monocytes. BNP and N-terminal (NT)-pro hormone BNP (NT-proBNP) are elevated in heart failure and seen in pregnant women alike. Within six to 12 weeks it returns to normal levels. Normal levels were shown to have good pregnancy outcomes in that the baby is healthy with normal birth weight and the mother is free of cardiovascular complications, whereas at elevated levels the pregnancy outcome was not favorable. NT-proBNP, when elevated in the pregnant patient, is a predictor of poor pregnancy outcomes, especially in patients with precursors. Testing for this peptide in pregnant women during the early stages of pregnancy could help determine the best course of action for a better outcome.
Identifiants
pubmed: 36699777
doi: 10.7759/cureus.32848
pmc: PMC9870182
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e32848Informations de copyright
Copyright © 2022, Esbrand et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Methodist Debakey Cardiovasc J. 2017 Oct-Dec;13(4):209-215
pubmed: 29744013
Clin Res Cardiol. 2021 Aug;110(8):1259-1269
pubmed: 33555408
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Perinat Med. 2017 Jul 26;45(5):577-583
pubmed: 28195551
Hypertension. 2020 Jan;75(1):91-97
pubmed: 31707840
Cardiol Ther. 2021 Dec;10(2):501-514
pubmed: 34213737
Medicine (Baltimore). 2018 Aug;97(31):e11516
pubmed: 30075517
Clin Biochem. 2019 May;67:12-15
pubmed: 30890412
Open Heart. 2020 Oct;7(2):
pubmed: 33077550
Circ Heart Fail. 2020 Feb;13(2):e006541
pubmed: 32065760
Eur Heart J. 2014 Mar;35(11):708-15
pubmed: 24334717
BMJ Open. 2018 Oct 17;8(10):e022562
pubmed: 30337314
PLoS One. 2019 Feb 7;14(2):e0211982
pubmed: 30730993
Arq Bras Cardiol. 2019 Dec;113(6):1129-1137
pubmed: 31664316
J Am Coll Cardiol. 2018 May 29;71(21):2431-2433
pubmed: 29793632
Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):293-321
pubmed: 12007084